Search company, investor...

JadoLabs

jado-tech.com

Stage

Other Investors | Alive

About JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Headquarters Location

Pfotenhauerstrasse 108

1307,

Germany

Missing: JadoLabs's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: JadoLabs's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing JadoLabs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

JadoLabs is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

D

Diabetes

1,899 items

JadoLabs Frequently Asked Questions (FAQ)

  • What is JadoLabs's latest funding round?

    JadoLabs's latest funding round is Other Investors.

  • Who are the investors of JadoLabs?

    Investors of JadoLabs include Max-Planck-Gesellschaft zur Forderung der Wissenschaften, EMBL Ventures, Stadtsparkasse Dresden, Dresden Fonds, SIB & Innovation and 6 more.

  • Who are JadoLabs's competitors?

    Competitors of JadoLabs include Humanetics, Asuragen, Inhibikase Therapeutics, Integral Molecular, Intarcia Therapeutics, Metabolic Solutions Development, Rigel Pharmaceuticals, Gamida Cell, Actinobac Biomed, Altor BioScience and 25 more.

Compare JadoLabs to Competitors

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

T
Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.

E
Embera NeuroTherapeutics

Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing treatments for to potentially treat a range of addictions located in the greater Boston, MA area.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.